Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis.

IF 2.1 4区医学 Q3 CLINICAL NEUROLOGY

European Neurology Pub Date : 2023-01-01 Epub Date: 2023-07-20 DOI:10.1159/000532022

Marek Peterka, Martin Valis, Ondrej Soucek, Jan Krejsek, Lukáš Sobisek, Ilona Sejkorova, Blanka Klimova, Pavel Stourac, Zbysek Pavelek, Michal Novotny

{"title":"Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis.","authors":"Marek Peterka, Martin Valis, Ondrej Soucek, Jan Krejsek, Lukáš Sobisek, Ilona Sejkorova, Blanka Klimova, Pavel Stourac, Zbysek Pavelek, Michal Novotny","doi":"10.1159/000532022","DOIUrl":null,"url":null,"abstract":"Introduction: Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations.Methods: Sixty Caucasian female patients with relapsing-remitting MS undergo blood sample testing for 15 blood parameters at baseline, 1 month, 3 months, and 6 months after treatment by GA or IFN (started as their first-line DMD).Results: A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%.Conclusion: Innate immunity has long been neglected in MS immunopathology. The findings suggest that IFN treatment may modulate the immune response in MS by affecting monocyte function and may provide insight into the mechanisms of action of IFN in MS.","PeriodicalId":12065,"journal":{"name":"European Neurology","volume":" ","pages":"334-340"},"PeriodicalIF":2.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623392/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000532022","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations.

Methods: Sixty Caucasian female patients with relapsing-remitting MS undergo blood sample testing for 15 blood parameters at baseline, 1 month, 3 months, and 6 months after treatment by GA or IFN (started as their first-line DMD).

Results: A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%.

Conclusion: Innate immunity has long been neglected in MS immunopathology. The findings suggest that IFN treatment may modulate the immune response in MS by affecting monocyte function and may provide insight into the mechanisms of action of IFN in MS.

Abstract Image

查看原文本刊更多论文

干扰素Beta-1a与醋酸格拉默：一组多发性硬化症女性先天免疫的变化。

引言：多发性硬化症（MS）是一种慢性炎症性自身免疫性脱髓鞘疾病，可继发导致轴突丢失和相关的脑萎缩。疾病修饰药物（DMD）以前曾因其影响特异性免疫的能力而被研究。本研究研究了干扰素β-1a（INF）和醋酸格拉默（GA）给药对先天免疫细胞群变化的影响。方法：60例复发-缓解型多发性硬化症的白人女性患者分别在基线、1个月、3个月、4个月和6个月进行了15项血液参数的血样检测，结果：在接受干扰素治疗的患者组中，单核细胞参数（相对计数）在6个月后的变化具有统计学意义。中位数增加27.8%。其他15个研究参数的变化为10-20%。结论：先天免疫在MS免疫病理学中长期被忽视。研究结果表明，IFN治疗可能通过影响单核细胞功能来调节MS的免疫反应，并可能深入了解IFN在MS中的作用机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Neurology 医学-临床神经学

CiteScore

4.40

自引率

4.20%

发文量

审稿时长

4-8 weeks

期刊介绍： ''European Neurology'' publishes original papers, reviews and letters to the editor. Papers presented in this journal cover clinical aspects of diseases of the nervous system and muscles, as well as their neuropathological, biochemical, and electrophysiological basis. New diagnostic probes, pharmacological and surgical treatments are evaluated from clinical evidence and basic investigative studies. The journal also features original works and reviews on the history of neurology.